Message Font: Serif | Sans-Serif
No. of Recommendations: 0
Bergen Brunswig will acquire 100% of the capital stock of PharMerica and give shareholders of PhrMerica a fixed exchange ratio of 0.275 of a share of Bergen Brunswig common stock for each share of PharMerica common stock. Bergen Brunswig will issue approximately 25 million shares in the merger and will convert PharMerica stock options into Bergen Brunswig options at the exchange ratio. Bergen Brunswig is expected to assume approximately $580 million of PharMerica's long-term debt. Based upon the closing stock price of Bergen Brunswig on January 8, 1999, the implied value of the transaction would be approximately $1.4 billion. PharMerica has 89.7 million fully diluted shares outstanding and upon completion of the
merger, PharMerica shareholders will own approximately 18% of the combined corporation on a fully diluted basis. To read the complete press release, highlight "news" in the data box to the right of the company name above.
Print the post  


When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.